We are live on
!
Find out more
DM
Deerfield Management Portfolio holdings
AUM
$8.48B
1-Year Est. Return
99.04%
This Fund
S&P 500
This Quarter
Est. Return
+33.56%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$5.42B
AUM Growth
+$877M
(+19%)
Cap. Flow
-$870M
Cap. Flow
% of AUM
-16.07%
Top 10 Holdings %
Top 10 Hldgs %
57.84%
Holding
236
New
154
Increased
21
Reduced
12
Closed
14
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Oscar Health
OSCR
|
+$77.6M |
| 2 |
Baxter International
BAX
|
+$48.1M |
| 3 |
Revolution Medicines
RVMD
|
+$32.2M |
| 4 |
SWTX
SpringWorks Therapeutics
SWTX
|
+$26.2M |
| 5 |
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
|
+$22.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
|
+$38.5M |
| 2 |
Neurocrine Biosciences
NBIX
|
+$36M |
| 3 |
ACH
Accendra Health
ACH
|
+$21.8M |
| 4 |
MRUS
Merus
MRUS
|
+$20M |
| 5 |
Roivant Sciences
ROIV
|
+$18.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 78.17% |
| 2 | Technology | 0.1% |
| 3 | Industrials | 0.09% |
| 4 | Consumer Discretionary | 0.08% |
| 5 | Consumer Staples | 0.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
126
Blue Owl Capital
OWL
$6.64B
| $271K | 0.01% |
+18,216
| New | +$245K |
|
127
Archer Daniels Midland
ADM
$39.6B
| $270K | 0.01% |
+3,742
| New | +$274K |
|
128
Nucor
NUE
$59.9B
| $269K | 0.01% |
+1,545
| New | +$245K |
|
129
Collegium Pharmaceutical
COLL
$1.16B
| $267K | ﹤0.01% |
+8,667
| New | +$217K |
|
130
Arvinas
ARVN
$528M
| $264K | ﹤0.01% |
+6,419
| New | +$150K |
|
131
Cytokinetics
CYTK
$10.9B
| $264K | ﹤0.01% |
+3,164
| New | +$115K |
|
132
Northern Trust
NTRS
$22.2B
| $262K | ﹤0.01% |
+3,100
| New | +$229K |
|
|
CDMO
133
DELISTED
Avid Bioservices, Inc. Common Stock
CDMO
| $257K | ﹤0.01% |
+39,576
| New | +$255K |
|
|
VGR
134
DELISTED
Vector Group Ltd.
VGR
| $256K | ﹤0.01% |
+22,680
| New | +$246K |
|
135
General Motors
GM
$81.7B
| $254K | ﹤0.01% |
+7,076
| New | +$219K |
|
136
Lockheed Martin
LMT
$133B
| $253K | ﹤0.01% |
+558
| New | +$247K |
|
137
Pinnacle West Capital
PNW
$12.9B
| $252K | ﹤0.01% |
+3,512
| New | +$258K |
|
138
Hallador Energy
HNRG
$697M
| $252K | ﹤0.01% |
+28,506
| New | +$360K |
|
|
BDN
139
Brandywine Realty Trust
BDN
$521M
| $250K | ﹤0.01% |
+46,297
| New | +$203K |
|
|
TOIIW
140
The Oncology Institute Warrant
TOIIW
$4.45M
| $250K | ﹤0.01% |
1,250,000
| – | – |
|
|
SVC
141
Service Properties Trust
SVC
$1.09B
| $250K | ﹤0.01% |
+5,854
| New | +$221K |
|
142
American Eagle Outfitters
AEO
$3.02B
| $250K | ﹤0.01% |
+11,813
| New | +$220K |
|
143
Customers Bancorp
CUBI
$2.68B
| $248K | ﹤0.01% |
+4,311
| New | +$187K |
|
144
ResMed
RMD
$30.1B
| $248K | ﹤0.01% |
+1,439
| New | +$221K |
|
145
Yelp
YELP
$1.5B
| $247K | ﹤0.01% |
+5,227
| New | +$231K |
|
146
Box
BOX
$4.37B
| $247K | ﹤0.01% |
+9,651
| New | +$244K |
|
147
3M
MMM
$94.3B
| $243K | ﹤0.01% |
+2,658
| New | +$213K |
|
148
Marathon Petroleum
MPC
$89.5B
| $242K | ﹤0.01% |
+1,632
| New | +$242K |
|
149
Unum
UNM
$14.1B
| $241K | ﹤0.01% |
+5,333
| New | +$243K |
|
150
Ecolab
ECL
$79.7B
| $238K | ﹤0.01% |
+1,202
| New | +$216K |
|
Similar funds
FT
GRQ
PCM
VA
QC
IC
NW
AAF
Deerfield Management's Q4 2023 Portfolio in Review
As of Q4 2023, Deerfield Management held 236 positions worth $5.42B, up 19% from $4.54B the previous quarter. Its ten largest holdings account for 58% of the portfolio.
Deerfield Management withdrew a net $870M in Q4 2023, closing 14 positions and reducing 12 holdings. Its most notable exit was Intercept Pharmaceuticals, Inc., an estimated $38.5M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 78% of assets, up from 68% a quarter earlier, followed by Technology and Industrials.
Against the trend, Deerfield Management opened a new position in Oscar Health worth $103M.
- Deerfield Management's largest Q4 2023 buy was Oscar Health: 11,246,820 shares worth $103M.
- Deerfield Management added most to Revolution Medicines in Q4 2023, an estimated $32.2M increase.
- Deerfield Management's biggest Q4 2023 reduction was Neurocrine Biosciences, cutting an estimated $36M.
- Deerfield Management fully exited Intercept Pharmaceuticals, Inc. in Q4 2023, selling an estimated $38.5M.
- Deerfield Management's ten largest holdings make up 58% of its $5.42B portfolio in Q4 2023.
- Deerfield Management opened 154 new positions and closed 14 in Q4 2023.
- Deerfield Management's portfolio value rose 19% quarter-over-quarter to $5.42B.
Based on Deerfield Management's 13F filing for Q4 2023, filed 14 Feb 2024.